Skip to main content
ETONEton Pharmaceuticals, Inc.Buy Wait6.8·$60.85
Buy WaitModerate Confidence
Investment thesis

Eton is a small-cap with explosive revenue growth, elite margins and strong momentum, but poor cash conversion, heavy insider selling and a thin 17.4% gap to the analyst target against 15.0% downside limit the case for more than a starter position.

Thesis pillars

  • Elite Margins And Returns→Stable
  • Explosive Revenue Growth→Stable
  • Earnings Beat Recovery↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 8, 2026, based on the 10-K filed Mar 19, 2026

Full reasoning →

Open full analysis

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis

Breakout setup

Buy WaitVALUE-TRAP 1/5GrowthQualityModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Wait for pullback to $57.81. At $60.85 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.

Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), plus... Read more

$60.85+12.8% A.UpsideScore 6.8/10#5 of 41 Drug Manufacturers - Specialty & Generic
QualityF-score8 / 9FCF yield0.80%
Entry $57.81(Default 5pct Sticky)Stop $53.76Target $68.64(analyst − 15%)A.R:R 0.8:1
Analyst consensus$80.75+32.7%4 analysts with price targets
$68.64our TP
$60.85price
$80.75mean
$82

Wait for pullback to $57.81. At $60.85 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.01, quality 8.6/10, growth 10.0/10). | CRISIS regime: wait for market stabilization. Score 6.8/10, moderate confidence.

Passes 5/8 gates (positive momentum, news events none recent, earnings proximity 123d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.

10-K grounded · weekly refresh

About Eton Pharmaceuticals, Inc.

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals markets eight rare-disease products spanning pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), most acquired and relaunched under Eton's own commercial infrastructure since 2020. INCRELEX targets patients with severe primary IGF-1 deficiency across 40 territories, ALKINDI SPRINKLE addresses an estimated 10,000 U.S. children with adrenal insufficiency, and pipeline candidate ET-600 carries an FDA PDUFA target action date of February 25, 2026.

Eton's model centers on acquiring under-appreciated, already-characterized drug assets — largely via the FDA's 505(b)(2) pathway, which lets the company reference existing safety and efficacy data rather than run costly ground-up trials — and then commercializing them through an internal sales force targeting pediatric endocrinologists and specialty pharmacies that handle patient reimbursement support. Three of the eight marketed products (Carglumic Acid, Betaine Anhydrous, Nitisinone) are generic versions of already-approved rare-disease drugs, while INCRELEX and GALZIN were acquired and relaunched in December 2024. Manufacturing is fully outsourced to third-party contract manufacturing organizations based mostly in the U.S. and Europe, and the pipeline includes ET-600 (diabetes insipidus), Amglidia (licensed from AMMTeK for neonatal diabetes mellitus, roughly 300 U.S. patients), and the ZENEO needle-free hydrocortisone autoinjector.

Show full overview

Eton's rare-disease pricing is increasingly exposed to federal drug-pricing reform rather than patent-cliff risk, since none of its generic-version products (Carglumic Acid, Betaine Anhydrous, Nitisinone) carry patent protection at all. The 10-K flags that Inflation Reduction Act mechanisms — inflation-based Medicare rebates, the redesigned Part D benefit, and potential future price-negotiation selection — could compress net prices as the product mix and Medicare utilization evolve, even though rare-disease volumes are typically too small today to trigger negotiation. Because ALKINDI SPRINKLE and KHINDIVI are protected only by patents expiring between 2032 and 2043, Eton's medium-term moat rests on formulation exclusivity and 505(b)(2) data protection rather than composition-of-matter patents.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Eton Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 17, 2026

Recent Developments — Eton Pharmaceuticals, Inc.

Latest item Nov 17, 2026 · Generated 2026-11-22T11:27:12Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 25, 2027123d to earnings· next earnings call

Thesis

Rewards
V7 crisis quality shield: -0.3 vs -1.5 (Q=8.6)
Sector modifier (Healthcare): +0.8
High-quality business
Risks
No bear case signals

Key Metrics

P/E (TTM)39.5
P/E (Fwd)18.4
Mkt Cap$1.8B
EV/EBITDA35.1
Profit Mgn35.3%
ROE90.6%
Rev Growth157.9%
Beta0.83
DividendNone
Analysts with ratings10

Quality Signals

Piotroski F8/9MoatWideCompounder✓

Options Flow

P/C0.05bullish
IV71%elevated

Material Events(8-K, last 90d)

  • 2026-04-16Item 5.02MEDIUM
    Judith Matthews appointed EVP, Accounting and Finance, to succeed James Gruber as CFO, Corporate Secretary and Treasurer effective June 1, 2026. Gruber remains through May 31, 2026 then enters a six-month consulting agreement; clean, planned handoff with successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 ceiling hits

GatesA.R:R 0.8 < 1.5@spotINSIDER 0.76%=EXTREMEExecutive change: officer departure/appointmentMomentum 5.5>=5.5NEWS EVENTS NONE RECENTEARNINGS PROXIMITY 123d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
63 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $47.03Resistance $70.64

Price Targets

$54
$58
$69
A.Upside+12.8%
A.R:R0.8:1

Position Sizing

ConvictionHigh conviction
Suggested %0.5%
Max %1%
RegimeCrisis

Risk Alerts

! CRISIS regime: all BUY_NOW downgraded to BUY_WAIT
! asymmetry at 0.8 (below the engine's 1.5 threshold)@spot
! Insider activity: 0.76%=extreme

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-25 (123d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ETON stock a buy right now?

Wait for pullback to $57.81. At $60.85 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.01, quality 8.6/10, growth 10.0/10). | CRISIS regime: wait for market stabilization. Target $68.64 (+12.8%), stop $53.76 (−13.2%), A.R:R 0.8:1. Score 6.8/10, moderate confidence.

What is the ETON stock price target?

Take-profit target: $68.64 (+12.8% upside). Target $68.64 (+12.8%), stop $53.76 (−13.2%), A.R:R 0.8:1. Stop-loss: $53.76.

Is ETON overvalued or undervalued?

Eton Pharmaceuticals, Inc. trades at a P/E of 39.5 (forward 18.4). TrendMatrix value score: 5.2/10. Verdict: Buy (Wait for Entry).

What do analysts say about ETON?

10 analysts rate ETON, with a consensus score of 4.1/5. 4 analysts publish price targets averaging $81.

What does Eton Pharmaceuticals, Inc. do?Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across...

Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), plus five late-stage pipeline candidates including ET-600, which carries an FDA PDUFA target action date of February 25, 2026. The company relies on third-party contract manufacturers for all products and pursues the FDA's 505(b)(2) pathway, acquiring under-appreciated development assets rather than originating novel compounds

Related stocks: SUPN (Supernus, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · KMDA (Kamada Ltd.)
Home › Stocks › ETON

Latest news

Latest News

GuruFocus53d ago
MarketBeat53d ago
Chart Mill53d ago
Moomoo116d agoEarnings
Marketscreener.com116d agoFda Decision
Investing.com South Africa116d agoFda Decision
Yahoo Finance116d agoFda Decision
New Statesman25d ago
AD HOC NEWS60d agoEarnings
BusinessMirror67d ago
Simply Wall Street39d agoProduct
Seeking Alpha39d ago
MarketBeat39d agoAnalyst
Benzinga11d ago
Yahoo Finance11d agoProduct
Investing.com Nigeria11d ago
Yahoo Finance11d agoEarnings
GuruFocus11d ago
Yahoo Finance46d ago
Simply Wall Street46d agoProduct
Loading more...